Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics
The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) – a preclinical asset that targets a specific protein in the complement pathway.
Read More
Tag: Silence Theraputics
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
